Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OncoZenge AB (publ) (ONCOZ.ST)
SEK6.40
-0.25 (-3.76%)
SE STO Healthcare Biotechnology
Address
Gustavslundsvagen 34 167 51
Bromma, SE
Bromma, SE
CEO
Stian Kildal
Website
oncozenge.se
IPO
2021-02-12
ISIN SE0015504097
Description
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK6.40
-0.25 (-3.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
37.9K
Beta
1.36
Float Shares
7.73M
Free Float %
55.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.56% | -12.21% | +6.67% | +3.90% | +14.70% | -2.88% | +21.90% | +4.92% | -36.32% | -47.70% | -47.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.40
DCF (Unlevered)
0.86
-86.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-12.98
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+266,300.0% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-77.0% Q1'26: -14,310.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.7%
-
EBIT margin Biotechnology: +0.0%-595.7%
-
ROIC Biotechnology: -16.1%-496.1% Q1'26: -392.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.6% Q1'26: +13.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.47× Q1'26: -0.28× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
3.0K
est: 4.0K (-25.0%)
|
1.0K
est: 2.78M (-100.0%)
|
2.66M
est: 3.00M (-11.2%)
|
5.00M
5.00M – 5.00M
+66.7% YoY
|
14.40M
14.40M – 14.40M
+188.0% YoY
|
20.30M
20.30M – 20.30M
+41.0% YoY
|
| EBITDA |
7.27M
est: 799.00 (+909,286.7%)
|
-8.69M
est: 556.2K (-1,661.5%)
|
-15.87M
est: 600.0K (-2,745.0%)
|
1,000.0K
1,000.0K – 1,000.0K
+66.7% YoY
|
2.88M
2.88M – 2.88M
+188.0% YoY
|
4.06M
4.06M – 4.06M
+41.0% YoY
|
| EBIT |
-15.90M
est: -799.00 (-1,990,137.8%)
|
-8.69M
est: -556.2K (-1,461.5%)
|
-15.87M
est: -600.0K (-2,545.0%)
|
-1,000.0K
-1,000.0K – -1,000.0K
-66.7% YoY
|
-2.88M
-2.88M – -2.88M
-188.0% YoY
|
-4.06M
-4.06M – -4.06M
-41.0% YoY
|
| Net Income |
-15.90M
est: -12.20M (-30.3%)
|
-8.69M
est: -8.25M (-5.3%)
|
-15.94M
est: -9.70M (-64.3%)
|
-12.13M
-12.13M – -12.13M
-25.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
8.51M
est: 9.22M (-7.7%)
|
8.68M
est: 6.41B (-99.9%)
|
—
est: 6.91B (-100.0%)
|
11.52B
11.52B – 11.52B
+66.7% YoY
|
33.18B
33.18B – 33.18B
+188.0% YoY
|
46.78B
46.78B – 46.78B
+41.0% YoY
|
| EPS |
-1.36
est: -1.01 (-35.2%)
|
-0.74
est: -0.68 (-8.8%)
|
-1.31
est: -0.80 (-63.8%)
|
-1.00
-1.00 – -1.00
-25.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
-158.7K
Shares Outstanding
14.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stian Kildal | Chief Executive Officer | 2M | male |
| Ida Sparrfeldt | Chief Auditor | — | — |
| Marie-Louise Helena Fjallskog | Chief Medical Officer | — | — |
| Michael Owens | Chief Financial Officer | — | male |
| Tuulikki Lindmark | Head of CMC in Phase 3 Sponsor Team | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONCOZ.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
